资料显示，济民健康管理股份有限公司位于浙江省台州市黄岩区北院路888号，成立日期1996年12月24 日，上市日期2015年2月17日，公司主营业务涉及医疗器械的研发、生产和销售,医疗服务,以及大输液产 品研发、生产和销售。主营业务收入构成为：医药制造52.07%，医疗服务46.01%，医药贸易1.54%，其 他(补充)0.38%。 截至9月30日，济民健康股东户数5.81万，较上期增加107.00%；人均流通股9035股，较上期减少 51.69%。2025年1月-9月，济民健康实现营业收入5.45亿元，同比减少20.21%；归母净利润-7715.04万 元，同比减少371.51%。 2月25日，济民健康涨1.68%，成交额7577.07万元。两融数据显示，当日济民健康获融资买入额400.17 万元，融资偿还379.04万元，融资净买入21.13万元。截至2月25日，济民健康融资融券余额合计1.69亿 元。 融资方面，济民健康当日融资买入400.17万元。当前融资余额1.69亿元，占流通市值的3.55%，融资余 额低于近一年20%分位水平，处于低位。 融券方面，济民健康2月25日融券偿还0.00股，融券卖出3 ...

分红方面，三诺生物A股上市后累计派现15.12亿元。近三年，累计派现3.44亿元。 融券方面，三诺生物2月25日融券偿还2500.00股，融券卖出600.00股，按当日收盘价计算，卖出金额 1.09万元；融券余量12.05万股，融券余额219.19万元，超过近一年90%分位水平，处于高位。 资料显示，三诺生物传感股份有限公司位于湖南省长沙高新技术产业开发区谷苑路265号，成立日期 2002年8月7日，上市日期2012年3月19日，公司主营业务涉及以生物传感技术为基础的相关慢性疾病即 时检测(POCT)产品的研发、设计、生产和销售。主营业务收入构成为：血糖监测系统73.29%，糖尿病 营养、护理等辅助产品6.59%，糖化血红蛋白检测系统5.03%，血脂检测系统4.14%，血压计4.11%， iPOCT监测系统3.94%，经营品2.05%，其他0.85%。 截至9月30日，三诺生物股东户数2.46万，较上期增加58.52%；人均流通股18347股，较上期减少 37.47%。2025年1月-9月，三诺生物实现营业收入34.53亿元，同比增长8.52%；归母净利润2.11亿元，同 比减少17.36%。 2月25日，三 ...

Core Insights - Zhengzhou is set to host over 10 exhibitions in March, covering diverse sectors such as education, retail, and catering, aimed at enhancing economic and trade cooperation and promoting industrial collaboration for high-quality development in the region [1][2]. Group 1: Exhibition Schedule - The "Great Instruments · Great Journey 2026 China (Zhengzhou) Aerospace National Defense Science Popularization Carnival" will take place from March 1 to 4 [2]. - The "China Zhengzhou Retail Supply Chain Exhibition and China Zhengzhou Retail Private Brand Exhibition" along with the "Zhengzhou Supermarket Processed Food Exhibition" is scheduled for March 6 to 7 [2]. - The "Second Henan Education Logistics Expo and School-Enterprise Docking Conference" and the "Second Henan Smart Group Meal and Catering Supply Chain Expo" will occur from March 6 to 8 [2]. - The "2026 China Hair Products Spring Trading Fair" is set for March 16 to 18 [2]. - The "2026 Spring (Zhengzhou) 45th Central Plains Advertising Exhibition" and the "2026 Central China (Zhengzhou) Decorative Painting and Frame and Soft Decoration Exhibition" will be held from March 18 to 20 [2]. - The "7th China Health Industry Brand Exhibition" is scheduled for March 19 to 20 [2]. - The "48th Central Plains Medical Devices (Spring 2026) Exhibition" and the "2026 Central China Dental (Zhengzhou) Equipment and Materials Exhibition" will take place from March 23 to 25 [2]. - The "38th Huaxia Home Expo" and the "23rd Central Plains Agricultural Products Trading and Information Exchange Conference" are set for March 28 to 29 [2]. - The "24th China (Zhengzhou) Education Innovation Conference" and the "24th China (Zhengzhou) Education Project Franchise and Education Technology Exhibition" along with the "2026 (China) Zhengzhou Digital Industry Expo and the 17th Central and Western IT Products Expo" and the "China (Zhengzhou) Consumer Electronics Expo" will be held from March 31 to April 2 [2].

Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-ValvePlus products from the New Zealand Medicines and Medical Devices Safety Authority, which will accelerate the global commercialization of its product portfolio [1] Group 1: Product Approval - The Ken-Valve and LuX-ValvePlus systems have recently obtained registration approval in New Zealand [1] - The approval is expected to enhance the company's market presence and facilitate the commercialization of these products [1] Group 2: Market Recognition - The products have gained widespread recognition in the market due to their design advantages and ongoing clinical trials [1] - Continuous promotion of the therapies has contributed to the positive reception of the products [1] Group 3: Strategic Goals - The company aims to expedite the global commercialization process of its product lineup to achieve its long-term strategic objectives [1]

Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-Valve Plus products in New Zealand, which will accelerate the global commercialization of its product portfolio [1] Group 1: Product Approval - Ken-Valve and LuX-Valve Plus have been approved by the New Zealand Medicines and Medical Devices Safety Authority [1] - The approval is expected to enhance the company's market presence and recognition due to the design advantages and ongoing clinical trials [1] Group 2: Commercialization Strategy - The company is actively promoting the commercialization of these two products in New Zealand [1] - The approval aligns with the company's long-term strategic goals for global market expansion [1]

据此前招股书，天星医疗是一家专注于运动医学整体临床解决方案的创新型医疗器械公司。据灼识咨询数据，按2024年销售收入计，天星医疗是中国最大的 国产运动医学公司。 截至最后实际可行日期，天星医疗拥有国内最全面的运动医学产品，主要涵盖植入物、有源设备及相关耗材、手术工具等52款产品，可以提供整体临床运动 医学解决方案。第三类医疗器械20款，5款产品在中国市场上所有品牌中首个获批并应用于临床，10款产品在国产品牌中首个获批并应用于临床。此外，天 星医疗在运动医学及智能康复领域的在研产品超过35个。 于往绩记录期间，依托多元化的产品矩阵，公司在中国市场实现了深度渗透：截至2022年12月31日，公司的产品已经进入医院数量超过1,000家，截至2024 年12月31日已增至3,000余家，其中三级医院超过1,000家。 北京天星医疗股份有限公司(简称：天星医疗)于2025年8月26日所递交的港股招股书满6个月，于2026年2月26日失效，递表时中信证券、建银国际为其联席 保荐人。 | 26/08/2025 | 北京天星醫療股份有限公司 | | --- | --- | | | 09/09/2025 整體協調人公告 - 委 ...

Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-Valve Plus products in New Zealand, which will accelerate its global commercialization efforts [1] Group 1: Product Approval - The Ken-Valve and LuX-Valve Plus have recently obtained registration approval from the New Zealand Medicines and Medical Devices Safety Authority [1] - The approval is expected to enhance the company's market presence and facilitate the commercialization of these products in New Zealand [1] Group 2: Market Recognition - The products have gained widespread recognition in the market due to their design advantages, ongoing clinical trials, and continuous therapy promotion efforts [1] - The successful registration of these two key products aligns with the company's long-term strategic goals [1]

Group 1: Economic Cooperation and Policies - The Chinese government expresses hope for the U.S. to view the implementation of the Phase One trade agreement objectively and rationally, urging against blame-shifting and provocations [1] - The Shanghai government has announced a reduction in housing purchase restrictions, including an increase in the maximum loan amount for first-time homebuyers from 1.6 million to 2.4 million yuan, with potential increases for families with multiple children [1] - The Guangzhou government is supporting financial product diversification to foster investment in technology and long-term projects [1] Group 2: Financial and Economic Forecasts - The International Monetary Fund (IMF) projects the U.S. GDP to grow by 2.6% in 2026, up from a previous forecast of 2.4% [3] - The Hong Kong government forecasts economic growth of 2.5% to 3.5% for the current year, with inflation rates expected at 1.7% and 1.8% respectively [1] - The "Inclusive Finance Prosperity Index" for January 2026 reached 49.60 points, indicating a slight increase, with financing conditions improving due to seasonal demand and policy support [1] Group 3: Company Announcements - Haiguang Information expects Q1 2026 revenue to be between 3.91 billion and 4.22 billion yuan, representing a year-on-year growth of 62.91% to 75.82% [1] - Transsion Holdings anticipates a 53.43% decline in net profit for 2025, down to 2.584 billion yuan [1] - Union Medical's net profit for 2025 is projected to increase by 49.60% to 1.888 billion yuan [1]

(一)股东会召开的时间：2026年2月25日 (二)股东会召开的地点：淄博市高新技术产业开发区泰美路7号新华医疗科技园办公楼三楼会议室 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次会议是否有否决议案：无 一、会议召开和出席情况 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，董事长王玉全先生主持，会议采用现场投票与网络投票相结合的方式表 决，符合《公司法》、《公司章程》等法律、法规及规范性文件的规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事11人，列席11人； 2、公司总经理巩报贤先生、副总经理兼董事会秘书李财祥先生、副总经理屈靖先生、董事兼财务总监 周娟娟女士、副总经理朱庆国先生、副总经理王加强先生出席了会议。 二、议案审议情况 (一)累积投票议案表决情况 1、关于换选公司董事的议案 ■ (二)涉及重大事项，5%以下股东的表决情况 ■ (三)关于议案表决的有关 ...

中泰证券指出，把握医药结构性行情，持续关注医药/医疗AI+，基本面有积极变化的轻筹码标的。本周 沪深300上涨0.36%，医药生物下滑0.81%，处于31个一级子行业第21位，本周医疗服务上涨0.22%，化 学制药、生物制品、医疗器械、中药、医药商业分别下跌0.54%、0.89%、1.07%、1.75%、2.68%。本周 医药行情分明显，AI医疗、前期回调明显的小核酸相关标的、基本面有边际变化且机构筹码较轻的部 分个股表现亮眼。我们认为医药作为兼具科技和消费属性的板块，在市场行情的轮动中将持续呈现结构 性行情，关于科技属性，创新药板块已经历了过去一年来的急涨后回调，相比2025年年初的位置，普遍 标的估值合理，因此建议关注所在细分行业（优选小核酸、体内CAR、ADC、二代IO、protac等）及公 司本身基本面有边际变化且持续性有望兑现的标的，医药/医疗AI+则是近期热度持续高涨的新方向，除 关注赛道龙头外，建议关注主营业务非医药/医疗AI+相关，但积极拥抱相关技术并预期能够中短期内兑 现估值弹性的标的；消费方面，目前2025年业绩预告基本发布完成，基本体现在当下股价，建议关注中 药、医美等消费医疗板块中积极 ...